Patents by Inventor Werner Rubas

Werner Rubas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STING AGONIST IMMUNOSTIMULATORY ANTIBODY DRUG CONJUGATES
    Publication number: 20260053942
    Abstract: The present disclosure is related to dual payload immunostimulatory antibody drug conjugates comprising at least STING agonist and at least one cytotoxic agent, pharmaceutical compositions thereof, and the use of the dual payload immunostimulatory antibody drug conjugates and compositions thereof for the treatment of diseases and disorders, including proliferative diseases
    Type: Application
    Filed: May 29, 2025
    Publication date: February 26, 2026
    Inventors: Gang Yin, Xiaofan Li, Helena Kiefel, Miao Wen, Kshama Doshi, Wadie Daniel Mahauad Fernandez, Werner Rubas, Junhao Yang, Amandeep Kaur Gakhal, Ravi Prakash Singh, Huiyong Hu, Wen Liu, Krishna Bajjuri, Xiangwei Zhu
  • Immunotherapeutic tumor treatment method
    Patent number: 12030940
    Abstract: Disclosed herein are methods in the field of cancer immunotherapy that involve the treatment of a subject having cancer by administering to the subject a toll-like receptor 7/8 (TLR7/8) agonist in combination with a long-acting IL-2R?-biased agonist and a programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) axis inhibitor, and related compositions, dosage forms, and kits.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: July 9, 2024
    Assignee: Nektar Therapeutics
    Inventors: Jonathan Zalevsky, Neel K. Anand, Haiying Cai, Bo-Liang Deng, Zhongxu Ren, Bhalchandra V. Joshi, Mary Tagliaferri, Werner Rubas, Saul Kivimae, Rhoneil L. Pena
  • IMMUNOTHERAPEUTIC TUMOR TREATMENT METHOD
    Publication number: 20210130467
    Abstract: Disclosed herein are methods in the field of cancer immunotherapy that involve the treatment of a subject having cancer by administering to the subject a toll-like receptor 7/8 (TLR7/8) agonist in combination with a long-acting IL-2R?-biased agonist and a programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) axis inhibitor, and related compositions, dosage forms, and kits.
    Type: Application
    Filed: August 17, 2018
    Publication date: May 6, 2021
    Inventors: Jonathan Zalevsky, Neel K. Anand, Haiying Cai, Bo-Liang Deng, Zhongxu Ren, Bhalchandra V. Joshi, Mary Tagliaferri, Werner Rubas, Saul Kivimae, Rhoneil L. Pena